HMNC Brain Health Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2010

Location

Munich Germany

Primary Industry

Biotechnology

About

Based in Munich, Germany, and founded in 2010, HMNC Holding GmbH provides precise therapies for depression and other neuropsychiatric disorders. In July 2021, the firm raised EUR 4 million in venture funding from Individual investors, with participation from investors. The company was founded by Prof. Dr. Dr. Dr. H.C. Mult. Florian Holsboer. The company develops therapies for mental health disorders by using its artificial intelligence platform and combining psychiatry, genomics, and analytics to it. The focus of the company therapies is on treatment-resistant depression (TRD), major depressive disorder (MDD), and anxiety disorders as well as personalized psychiatry. The company plans to use the July 2021 funding to accelerate its pipeline development toward market maturity which will allow preparation for two contract research organization (CRO) proof-of-concept studies, drive strategic growth initiatives, and strengthen the HMNC team.

Current Investors

Jahr Holding

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Mental Health Services, Analytics & Performance Software

Website

www.hmnc-brainhealth.com

Verticals

Artificial Intelligence

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.